MedTrace Logo

Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE)

NCT02544074 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2025-03-25

Study results available
· View outcomes & findings →

Summary

The Self-Administered Gerocognitive Examination (SAGE) is a valid and reliable cognitive assessment tool used to identify both Mild Cognitive Impairment (MCI) and early dementia. SAGE's self-administered feature, pen and paper format, and four equivalent interchangeable forms allows it to be given in almost any setting, does not require any staff time to administer and makes it practical to rapidly screen large numbers of individuals in the community or in their home.This trial is being conducted to study the validity of SAGE in a digital format (eSAGE) for cognitive screening.

The investigators will analyze the data to learn the correlations between eSAGE and gold standard neuropsychological testing designed to differentiate normal cognition from MCI and early dementia. The investigators will also find out whether the paper (SAGE) and electronic (eSAGE) versions of SAGE could be used interchangeably or not.

Addendum:

The eSAGE was previously validated in an earlier stage of this trial. It was initially designed for tablet use and the exact same test has recently been formatted for smartphone use.

This addendum is being conducted to study the validity of the smartphone eSAGE compared to the tablet eSAGE for cognitive screening.

Conditions

Interventions

BEHAVIORAL

neuropsychological testing

standard neuropsychological testing including brief standardized assessments

BEHAVIORAL

eSAGE testing

Neuropsychological testing including the eSAGE tablet and eSAGE smartphone

Sponsors & Collaborators

  • Brain Test, Inc.

    collaborator INDUSTRY

  • Ohio State University

    lead OTHER

Principal Investigators

  • Douglas Scharre, M.D. · Ohio State University

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2024-11-13
Completion
2024-11-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02544074 on ClinicalTrials.gov